{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:53:19Z","timestamp":1774536799872,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.coph.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T12:53:09Z","timestamp":1519303989000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Anti-hypertensive treatment in peripheral artery disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Costas","family":"Tsioufis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Andrikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Filis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.01.009_sbref0005","doi-asserted-by":"crossref","first-page":"e726","DOI":"10.1161\/CIR.0000000000000471","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2018.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.01.009_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2018.01.009_bib0020","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three year follow up and event rates in the international Reduction of Atherothrombosis for Continued Health Registry (REACH)","volume":"19","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2018.01.009_bib0025","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1001\/archinte.160.19.2934","article-title":"Determinants of peripheral arterial disease in the elderly: the Rotterdam study","volume":"160","author":"Meijer","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/HYPERTENSIONAHA.111.174359","article-title":"Can we use \u03b2-blocking agents in patients with peripheral artery disease?","volume":"58","author":"Clement","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_sbref0035","doi-asserted-by":"crossref","first-page":"h4865","DOI":"10.1136\/bmj.h4865","article-title":"Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults","volume":"351","author":"Emdin","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.coph.2018.01.009_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.113.01925","article-title":"Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study","volume":"63","author":"Garg","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_sbref0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","article-title":"Peripheral artery disease: epidemiology and global perspectives","volume":"14","author":"Fowkes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.coph.2018.01.009_sbref0050","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","article-title":"Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternationalVErapamil-SR\/TrandolaprilSTudy","volume":"55","author":"Bavry","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_bib0060","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2018.01.009_sbref0065","first-page":"ehx095","author":"Aboyans","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2018.01.009_sbref0070","author":"Whelton","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2018.01.009_bib0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"Ostergren","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2018.01.009_bib0085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_sbref0090","doi-asserted-by":"crossref","first-page":"e0140633","DOI":"10.1371\/journal.pone.0140633","article-title":"Angiotensin receptor blockers decrease the risk of major adverse cardiovascular events in patients with end-stage renal disease on maintenance dialysis: a nationwide matched-cohort study","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2018.01.009_bib0095","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2005.09.074","article-title":"Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease","volume":"47","author":"Feringa","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2018.01.009_bib0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia","volume":"20","author":"Armstrong","year":"2015","journal-title":"Vasc Med Lond Engl"},{"key":"10.1016\/j.coph.2018.01.009_bib0105","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.hjh.0000249692.96488.46","article-title":"Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial","volume":"24","author":"Zanchetti","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.coph.2018.01.009_bib0110","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2018.01.009_sbref0115","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s11606-014-2947-1","article-title":"Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT","volume":"29","author":"Piller","year":"2014","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0120","first-page":"CD003075","article-title":"Treatment of hypertension in peripheral arterial disease","volume":"12","author":"Lane","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2018.01.009_bib0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijsu.2010.12.006","article-title":"Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials","volume":"9","author":"Shahin","year":"2011","journal-title":"Int J Surg"},{"key":"10.1016\/j.coph.2018.01.009_sbref0130","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2018.01.009_bib0135","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 \u2013 Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.coph.2018.01.009_bib0140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","article-title":"\u03b2-Blockers in patients with intermittent claudication and arterial hypertension: results from the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial","volume":"58","author":"Espinola-Klein","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risc Score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Ankle Brachial Index Collaboration","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2018.01.009_bib0150","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/HJH.0b013e3283471151","article-title":"Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication","volume":"29","author":"Diehm","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.coph.2018.01.009_bib0155","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.1991.00400090063012","article-title":"\u03b2-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a metaanalysis of randomized controlled trials","volume":"151","author":"Radack","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0160","first-page":"CD005508","article-title":"Beta blockers for peripheral arterial disease","volume":"9","author":"Paravastu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2018.01.009_bib0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1248\/yakushi.124.825","article-title":"Beta-adrenergic blocking agents and intermittent claudication: systematic review","volume":"124","author":"Miyajima","year":"2004","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.coph.2018.01.009_sbref0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5551\/jat.27359","article-title":"Beta-blocker treatment does not worsen critical limb ischemia in patients receiving endovascular therapy","volume":"22","author":"Soga","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.coph.2018.01.009_sbref0175","doi-asserted-by":"crossref","first-page":"e5916","DOI":"10.1097\/MD.0000000000005916","article-title":"Impact of beta blockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry","volume":"96","author":"Mirault","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coph.2018.01.009_bib0180","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0002-9149(01)01521-1","article-title":"Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease","volume":"87","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coph.2018.01.009_bib0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pcad.2017.05.008","article-title":"Medical management of asymptomatic carotid artery stenosis","volume":"59","author":"Aday","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.coph.2018.01.009_bib0190","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1161\/STROKEAHA.114.005669","article-title":"Predictors of carotid thickness and plaque progression during a decade: the Multi-Ethnic Study of Atherosclerosis","volume":"45","author":"Tattersall","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.coph.2018.01.009_sbref0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccl.2014.09.001","article-title":"Management of extracranial carotid artery disease","volume":"33","author":"Ooi","year":"2015","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.coph.2018.01.009_bib0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIR.0b013e31820d8d78","volume":"124","author":"Brott","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2018.01.009_bib0205","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.STR.0000227223.90239.13","article-title":"Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials","volume":"37","author":"Wang","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.coph.2018.01.009_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IBPC.S5174","article-title":"Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials","volume":"2","author":"Cuspidi","year":"2009","journal-title":"Integr Blood Press Control"},{"key":"10.1016\/j.coph.2018.01.009_bib0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1472-8206.2010.00832.x","article-title":"Do all antihypertensive drugs improve carotid intima-media thickness?. A network meta-analysis of randomized controlled trials","volume":"25","author":"Tropeano","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.coph.2018.01.009_sbref0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa1505215","article-title":"Long-term results of stenting versus endarterectomy for carotid-artery stenosis","volume":"374","author":"Brott","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0230","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/01.HYP.31.3.823","article-title":"BP outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. EssaiMulticentrique Medicaments vs Angioplastie (EMMA) Study Group","volume":"31","author":"Plouin","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_bib0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.jhh.1000599","article-title":"Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group","volume":"12","author":"Webster","year":"1998","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.coph.2018.01.009_bib0240","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM200004063421403","article-title":"The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group","volume":"342","author":"Van Jaarsveld","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0245","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-150-12-200906160-00119","article-title":"Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial","volume":"150","author":"Bax","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2018.01.009_bib0250","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"Wheatley","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.01.009_sbref0255","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ndt\/gfu072","article-title":"Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials","volume":"30","author":"Caielli","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2018.01.009_bib0260","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ndt\/gfr496","article-title":"Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease","volume":"27","author":"Chrysochou","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2018.01.009_bib0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2362.2011.02577.x","article-title":"Diagnosis and management of fibromuscular dysplasia: an expert consensus","volume":"42","author":"Persu","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.coph.2018.01.009_bib0270","first-page":"36","article-title":"Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries","volume":"4","author":"Chrysant","year":"2014","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.coph.2018.01.009_bib0275","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/jch.12161","article-title":"Current status of angioplasty in atherosclerotic renal artery stenosis for the treatment of hypertension","volume":"15","author":"Chrysant","year":"2013","journal-title":"J ClinHypertens (Greenwich)"},{"key":"10.1016\/j.coph.2018.01.009_bib0280","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08037050701642766","article-title":"Treatment of renovascular hypertension by transluminal angioplasty-13 years experience in a single centre","volume":"16","author":"\u00d8vrehus","year":"2007","journal-title":"Blood Press"},{"key":"10.1016\/j.coph.2018.01.009_bib0285","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/0003319709335512","article-title":"Angioplasty for renal artery fibromuscular dysplasia in older hypertensive patients","volume":"60","author":"Thatipelli","year":"2009","journal-title":"Angiology"},{"key":"10.1016\/j.coph.2018.01.009_bib0290","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jvs.2008.05.030","article-title":"The long term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia","volume":"48","author":"Davies","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.coph.2018.01.009_bib0295","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/HYPERTENSIONAHA.110.152918","article-title":"Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis","volume":"56","author":"Trinquart","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2018.01.009_bib0300","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2018.01.009_bib0305","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T16:37:49Z","timestamp":1530031069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217301091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":61,"alternative-id":["S1471489217301091"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.01.009","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-hypertensive treatment in peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}